Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER).
暂无分享,去创建一个
Thomas Bachelot | Florence Dalenc | Thomas Filleron | Magali Lacroix-Triki | Frederic Commo | David Gentien | Fabrice André | Mario Campone | F. André | M. Lacroix-Triki | J. Bonneterre | H. Bonnefoi | M. Campone | V. Diéras | F. Dalenc | T. Bachelot | L. Lacroix | M. Arnedos | J. Ferrero | D. Gentien | T. Filleron | A. Gonçalves | Ludovic Lacroix | Hervé Bonnefoi | F. Commo | P. Cohen | Monica Arnedos | Véronique Dieras | Pascale Cohen | Jose Adélaide | Anthony Goncalves | Christelle Levy | Jean-Marc Ferrero | Jacques Bonneterre | Claudia Lefeuvre | Marta Jimenez | M. Jimenez | C. Lefeuvre | J. Adélaide | C. Lévy
[1] Yuan Jiang,et al. A probe-density-based analysis method for array CGH data: simulation, normalization and centralization , 2008, Bioinform..
[2] Michael Bittner,et al. Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] I. Ray-Coquard,et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] J. T. Thigpen. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study , 2011 .
[5] A. Børresen-Dale,et al. The landscape of cancer genes and mutational processes in breast cancer , 2012, Nature.
[6] E. S. Venkatraman,et al. A faster circular binary segmentation algorithm for the analysis of array CGH data , 2007, Bioinform..
[7] Eric Sauerbrei,et al. Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Thomas Bachelot,et al. Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer , 2013, Clinical Cancer Research.
[9] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[10] Suzanne F. Jones,et al. A Phase Ib Study of the Akt Inhibitor GDC-0068 with Docetaxel or mFOLFOX6 in Patients with Advanced Solid Tumors 3021 , 2012 .
[11] R. Arceci. Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing , 2012 .
[12] A. Joe,et al. Oncogene addiction. , 2008, Cancer research.
[13] J. Baselga,et al. Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy , 2012, Clinical Cancer Research.
[14] F. Markowetz,et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.
[15] G. Jayson,et al. Abstract B153: A phase I study evaluating the pharmacokinetics (PK) and pharmacodynamic (PD) activity of the dual PI3K/mTOR inhibitor GDC-0980 administered once weekly (QW). , 2011 .
[16] R. Simon,et al. Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.
[17] Nikhil Wagle,et al. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. , 2012, Cancer discovery.
[18] Adam A. Margolin,et al. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.
[19] F. André,et al. Biology-driven phase II trials: what is the optimal model for molecular selection? , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] A. Jemal,et al. Breast Cancer Statistics , 2013 .
[21] M. Mathieu,et al. Array CGH and PIK3CA/AKT1 mutations to drive patients to specific targeted agents: a clinical experience in 108 patients with metastatic breast cancer. , 2012, European journal of cancer.
[22] Spyro Mousses,et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer , 2007, Nature.
[23] Anthony Rhodes,et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2007, Archives of pathology & laboratory medicine.